Spine BioPharma
New York, US · Delaware corporation · 1 known investors
Developing non-surgical, non-opioid therapies for degenerative disc disease through targeted peptide injection.
Biotech
Founders & leadership
MR
Marc R. ViscogliosiDirector and Chief Executive Officer of the Issuer
FM
Fran MageeChief Technology Officer
JG
Jason GallagherChief Commercial Officer/Chief Operations Officer
JJ
John J. ViscogliosiDirector
TB
Thomas Bumol, PhDDirector
FC
Frank Cammisa, MDDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$384.8KraisedJun 2026 · 3 investors · PharmaceuticalsRule 506(b)
▶$384.8KraisedJun 2026 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Fran MageeExecutive Officer
- John J. ViscogliosiDirector
- Thomas Bumol, PhDDirector
- Marc R. ViscogliosiExecutive Officer, Director
- Frank Cammisa, MDDirector
- Offering amount
- $8.5M
- Amount sold
- $384.8K
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.5MraisedDec 2024 · 10 investors · PharmaceuticalsRule 506(b)
▶$13.5MraisedDec 2024 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas Bumol, PhDDirector
- Fran MageeExecutive Officer
- Jason GallagherExecutive Officer
- Marc R. ViscogliosiExecutive Officer, Director
- Frank Cammisa, MDDirector
- John J. ViscogliosiDirector
- Offering amount
- $23.5M
- Amount sold
- $13.5M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedOct 2023 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.4MraisedOct 2023 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frank Cammisa, MDDirector
- Marc R. ViscogliosiExecutive Officer, Director
- Fran MageeExecutive Officer
- John J. ViscogliosiDirector
- Thomas Bumol, PhDDirector
- Offering amount
- $15M
- Amount sold
- $2.4M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedAug 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.9MraisedAug 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frank Cammisa, MDDirector
- Fran MageeExecutive Officer
- John J. ViscogliosiDirector
- Thomas Bumol, PhDDirector
- Marc R. ViscogliosiExecutive Officer, Director
- Offering amount
- $13M
- Amount sold
- $1.9M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13MraisedFeb 2023 · 8 investors · PharmaceuticalsRule 506(b)
▶$13MraisedFeb 2023 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas Bumol, PhDDirector
- John J. ViscogliosiDirector
- Frank Cammisa, MDDirector
- Marc R. ViscogliosiExecutive Officer, Director
- Fran MageeExecutive Officer
- Offering amount
- $13M
- Amount sold
- $13M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13MraisedMar 2022 · 6 investors · PharmaceuticalsRule 506(b)
▶$13MraisedMar 2022 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas Bumol, PhDDirector
- John J. ViscogliosiDirector
- Fran MageeExecutive Officer
- Marc R. ViscogliosiExecutive Officer, Director
- Frank Cammisa, MDDirector
- Offering amount
- $30.4M
- Amount sold
- $13M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedApr 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedApr 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- LLC Viscogliosi Brothers,Executive Officer
- Marc R. ViscogliosiExecutive Officer
- John J ViscogliosiExecutive Officer
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Apr 2021
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5MraisedMar 2021 · 14 investors · PharmaceuticalsRule 506(b)
▶$5MraisedMar 2021 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- LLC Viscogliosi Brothers,Executive Officer
- John J ViscogliosiExecutive Officer
- Marc R. ViscogliosiExecutive Officer
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $25K
- First sale
- Mar 2021
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.